LITFULO helped more patients achieve moderate-to-normal eyebrows vs placebo at Week 24, and continued through Week 48[1,2,4] Percentages are based on the number of participants who had abnormal scores at baseline. Response is based on at least a 2-grade improvement from baseline or a normal score on the 4-point scale among the participants with an abnormal score at baseline. The EBA scale includes scores of 0 (none), 1 (minimal), 2 (moderate), and 3 (normal).[1,2,4]
Week 24: ref. 1 table 3 (%) ref. 2 table 1 (n). Week 48: ref. 4 figure S4C (%)
Eyebrow Assessment Scale[1,4]
0 = None Eyebrow
1 = Minimal Eyebrow
- Normal or decreased density of one or both eyebrows with large gap(s)
- Severely decreased density of one or both eyebrows with or without gap(s)
2 = Moderate Eyebrow
- Normal density of both eyebrows with short gap(s) that does not significantly distort the appearance of the eyebrows, OR
- Mildly decreased density of eyebrows with or without short gap(s), OR
- Moderately decreased density of eyebrows without short gap(s)
- There is visual definition of eyebrows at a distance of 3 feet
3 = Normal Eyebrow
- Normal density of both right and left eyebrows spanning usual length (ie, from glabella to near temple) and width. There are no gap(s)
Patients with EBA scores of 0-2 were included in the EBA assessments throughout the study.
Limitations and biases
- Participants with missing EBA/ELA data at a visit due to COVID-related reasons are excluded in the analyses at that visit[4]
- Participants with EBA/ELA missing data at a visit due to reasons unrelated to COVID-19 are considered as nonresponders for that visit[4]
- Percentages are calculated based on the number of participants who had abnormal scores at baseline[1,2]
Eyebrow responses were prespecified secondary endpoints not controlled for multiplicity. The results should be interpreted with caution and could represent chance findings.[2]
Note: There was no placebo after Week 24. These results do not reflect the patients who switched from placebo to LITFULO 50 mg treatment after Week 24.[1]
Participants with missing EBA/ELA data at a visit due to COVID-related reasons were excluded from the analysis at that visit; those with missing data due to reasons unrelated to COVID-19 were considered nonresponders for that visit.[4]
The EBA/ELA are clinician-reported measures that characterise eyebrow/eyelash hair loss on a 4-point ordinal scale.[2,4]
Inclusion in the study was not based on eyebrow or eyelash involvement. Of the patients who received LITFULO 50 mg (n=130) or placebo (n=131), 82% and 82% had abnormal eyebrows at baseline, respectively. And of the patients who received LITFULO 50 mg (n=130) or placebo (n=131), 73% and 74% had abnormal eyelashes at baseline, respectively.
See real results in real patients Before & after images LoadingEBA=eyebrow assessment; ELA=eyelash assessment.
References:1.LITFULO (ritlecitinib) SmPC. 2.King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10; 401(10392):1928. 4.King B, Zhang X, Harcha WG, et al. Supplement to: Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. April 13, 2023. doi:10.1016/S0140-6736(23)00222-2
LITFULO helped more patients achieve moderate-to-normal eyelashes vs placebo at Week 24, and continued through Week 48[1,2,4] Percentages are based on the number of participants who had abnormal scores at baseline. Response is based on at least a 2-grade improvement from baseline or a normal score on the 4-point scale among the participants with an abnormal score at baseline. The ELA scale includes scores of 0 (none), 1 (minimal), 2 (moderate), and 3 (normal).[1,2,4] Week 24: ref. 1 table 3 (%) ref. 2 table 1 (n). Week 48: ref. 4 figure S4D (%)
Eyelash Assessment Scale[1,4]
0 = None Eyelash
- No eyelashes of both right and left upper and lower eyelashes
1 = Minimal Eyelash
- Modestly or severely decreased density of and/or large gap(s) in one or both upper eyelashes
2 = Moderate Eyelash
- Normal density of both upper eyelashes without gap(s), and decreased density or gap(s) is present in one or both lower eyelashes, OR
- Normal density of both upper eyelashes with short gap(s), OR
- Mildly decreased density of one or both upper eyelashes with or without short gap(s)
3 = Normal Eyelash
- Normal density of both right and left upper and lower eyelashes from near medial canthus to near lateral canthus without any gap(s)
Patients with ELA scores of 0-2 were included in the ELA assessments throughout the study.
Limitations and biases:
- Participants with missing EBA/ELA data at a visit due to COVID-related reasons are excluded in the analyses at that visit[4]
- Participants with EBA/ELA missing data at a visit due to reasons unrelated to COVID-19 are considered as nonresponders for that visit[4]
- Percentages are calculated based on the number of participants who had abnormal scores at baseline[1,2]
Eyebrow responses were prespecified secondary endpoints not controlled for multiplicity. The results should be interpreted with caution and could represent chance findings.[2]
Note: There was no placebo after Week 24. These results do not reflect the patients who switched from placebo to LITFULO 50 mg treatment after Week 24.[1]
Participants with missing EBA/ELA data at a visit due to COVID-related reasons were excluded from the analysis at that visit; those with missing data due to reasons unrelated to COVID-19 were considered nonresponders for that visit.[4]
The EBA/ELA are clinician-reported measures that characterise eyebrow/eyelash hair loss on a 4-point ordinal scale.[2,4]
Inclusion in the study was not based on eyebrow or eyelash involvement. Of the patients who received LITFULO 50 mg (n=130) or placebo (n=131), 82% and 82% had abnormal eyebrows at baseline, respectively. And of the patients who received LITFULO 50 mg (n=130) or placebo (n=131), 73% and 74% had abnormal eyelashes at baseline, respectively.
See real results in real patients Before & after images LoadingEBA=eyebrow assessment; ELA=eyelash assessment.References:1.LITFULO (ritlecitinib) SmPC. 2.King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial.Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10; 401(10392):1928. 4.King B, Zhang X, Harcha WG, et al. Supplement to: Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial.Lancet. April 13, 2023. doi:10.1016/S0140-6736(23)00222-2